Home > News > India News > Article > Indias first mRNA Covid 19 vaccine to get Emergency Use Authorisation soon

India's first mRNA Covid-19 vaccine to get Emergency Use Authorisation soon

Updated on: 28 June,2022 12:13 AM IST  |  New Delhi
ANI |

The Drugs controller general of India (DCGI) is expected to give Emergency Use Authorisation to Gennova's mRNA vaccine any time soon

India's first mRNA Covid-19 vaccine to get Emergency Use Authorisation soon

Representative image


The Subject Expert Committee (SEC) in a meeting held on Friday recommended Emergency Use Authorisation (EUA) for India's first mRNA Covid-19 vaccine, sources told ANI on Tuesday.


The Drugs controller general of India (DCGI) is expected to give Emergency Use Authorisation to Gennova's mRNA vaccine any time soon.



The SEC under India's drug regulator found data submitted by Gennova Biopharmaceuticals satisfactory in the Friday meeting, people in the know told ANI.The company submitted data in April and provided additional data in May. 


Also read: Mumbai: Is current spike in Covid-19 cases ending?

Earlier in May, Gennova had released a statement to ANI regarding updates on submitting phase 3 data."Gennova is in communications with the regulatory agency and submitting all necessary data and information required for the product approval," said Gennova's spokesperson.

"Product development using innovative technologies like mRNA, a fourth-generation vaccine platform stable at 2 to 8 degrees Celcius, is a challenging journey during pandemic times," the spokesperson further said.

The company has conducted phase 2 and phase 3 data trials on 4000 participants to evaluate vaccine safety, immunogenicity and tolerability.

The vaccine - GEMCOVAC-19 - is the country's first homegrown mRNA Covid- 19 vaccine and is seen as a game-changer for the healthcare industry.

Register for FREE
to continue reading !

This is not a paywall.
However, your registration helps us understand your preferences better and enables us to provide insightful and credible journalism for all our readers.

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK